2023 Fall Clinical Virtual Grand Rounds
2023 Virtual Grand Rounds Session 3: March 8, 2023 - WCM: Your Questions Answered
About
Fall Clinical Virtual Grand Rounds consists of regularly scheduled CME sessions on a variety of dermatological diseases and tools, delivered by the top experts in dermatology.
Please join us for this week's session:
Wednesday, March 8, 2023
8 PM ET/ 5 PM PT
Winter Clinical Dermatology Conference- MIAMI: Your Questions Answered
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
March 8, 2023
March 8, 2024
Learning Objectives
At the completion of this activity, participants should be better able to:
Discuss current management advancement in dermatology from rashes through tumors
Compare strategies to manage dermatologic conditions from laser treatment through systemic therapies
Identify appropriate treatment options for dermatologic conditions based on patient and disease characteristics
Recognize the nuances of managing dermatologic conditions in skin of color
Underline strategies to optimize management in patients with dermatologic conditions
Intended Audience
Faculty
Seemal Desai, MD
Clinical Assistant Professor
Department of Dermatology
University of Texas Southwestern Medical Center
Dallas, TX
Boni Elewski, MD
James Elder Professor and Chair of Dermatology
University of Alabama at Birmingham
Birmingham, AL
Mark Nestor, MD, PhD
Director of Center for Clinical and Cosmetic Research
Voluntary Professor, Dermatology
University of Miami, Miller School of Medicine
Miami, FL
Darrell Rigel, MD, MS
Clinical Professor of Dermatology
Director, Melanoma Surveillance Clinic
Mount Sinai Icahn School of Medicine, New York, NY
Adjunct Professor, UT Southwestern Medical School
Consultant Dermatologist, Cooper Clinic, Dallas, TX
Lisa Swanson, MD
Pediatric Dermatologist
Ada West Dermatology
Boise, ID
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
CONFLICTS OF INTEREST/DISCLOSURES
In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer.
Disclosures are as follows:
Grant/Research Support: AbbVie, Incyte, Dermavant, AOBiome,
Consultant: Galderma, Almirall, Ferndale, BMS, AbbVie, Verrica, UCB, Ortho, Scientis, EPI, Avita, Eli Lilly, Leo, Pfizer, Incyte, L’Oreal, Beiersdorf, J&J
Speakers’ Bureau or Honoraria: Dermavant, Galderma, Pfizer
Grant/Research Support: Ortho Dermatology
Consultant: Ortho Dermatology
Grant/Research Support: CROMA Pharma, Galderma, Merz
Consultant: CROMA Pharma, Revian, Sensus
Speakers’ Bureau or Honoraria: Allergan, AMP, Galderma, Hugel, Sensus
Grant/Research Support: Castle Biosciences, SciBASE
Consultant: DermTech, Ferndale Laboratories, Inc., SciBase, VYNE Therapeutics
Speakers’ Bureau or Honoraria: Castle Biosciences
Advisory Board: Almirall, Beiersdorf, Inc., Castle Biosciences, Johnson and Johnson
Consultant: Janssen, Lilly, Ortho Dermatologics, Sanofi-Regeneron, Pfizer, LEO, Novan, Arcutis
Speakers’ Bureau or Honoraria: Ortho Dermatologics, Pfizer, Amgen, Sanofi-Regeneron, Almirall, Janssen, Lilly, Novartis, Abbvie, Incyte
The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.